Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Price Down 15.4% – Here’s Why

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) shares dropped 15.4% during mid-day trading on Friday . The company traded as low as $27.06 and last traded at $27.06. Approximately 785 shares were traded during mid-day trading, an increase of 283% from the average daily volume of 205 shares. The stock had previously closed at $31.99.

Swedish Orphan Biovitrum Stock Performance

The company has a market capitalization of $9.63 billion, a P/E ratio of 25.53 and a beta of 0.44. The business has a 50-day moving average of $29.99 and a 200-day moving average of $29.23. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.04 and a quick ratio of 0.71.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. The company had revenue of $641.33 million during the quarter, compared to the consensus estimate of $644.12 million. Swedish Orphan Biovitrum had a return on equity of 10.54% and a net margin of 15.07%.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.